Elsevier

Clinical Therapeutics

Volume 22, Issue 6, June 2000, Pages 792-793
Clinical Therapeutics

Letter to the editor

https://doi.org/10.1016/S0149-2918(00)90012-2Get rights and content

References (0)

Cited by (15)

  • Efficacy of Hylan G-F 20 and Sodium Hyaluronate in the treatment of osteoarthritis of the knee - A prospective randomized clinical trial

    2008, Knee
    Citation Excerpt :

    Whilst there is a general acceptance of the beneficial effects of HA, there still exists an ongoing debate about the degree of efficacy of these individual products [15,17]. Additionally there have been controversies in the therapeutic efficacy of cross-linked/non cross-linked and high/low molecular weight products [10,15,20,21,45]. This has prompted the need for well designed prospective randomized trials to resolve the continued uncertainty about the magnitude of therapeutic effects of various products.

  • Intra-articular hyaluronans: A review of product-specific safety profiles

    2003, Seminars in Arthritis and Rheumatism
    Citation Excerpt :

    Hyalgan was well tolerated in this population, with only 17 adverse events reported. These included local reaction to puncture (5), exudation in the articular space (6), local swelling (2), gastric discomfort (2), and allergic exanthema (1). Despite the excellent tolerability profile of Hyalgan shown in clinical trials and observed in clinical experience, there has been at least 1 published case study of a patient with calcium pyrophosphate dihydrate (CPPD) arthritis (pseudogout) presumably resulting from an IA injection of Hyalgan (20); 2 additional reports did not specify which HA product was used (21,22).

View all citing articles on Scopus
View full text